Albany, New York, USA (PRWEB) April 21, 2014

Transparency Market Research Reports included a detailed market survey and analysis trends on Micro-RNA Market. This report also includes more info about basic overview of the industry including definitions, applications and global market industry structure.

Micro-RNA is a small non-coding RNA molecule which is a vital component of genetic regulation. Set of micro-RNAs are present in plants and animals functioning in gene expression process. They are involved in the normal functioning of the eukaryotic cells. Biogenesis of micro-RNA is the basis for RNA interference drug discovery and research in therapeutics. Micro-RNAs are likely to be involved in biological processes by affecting the gene regulation. Research and development of micro-RNA based therapies are recently being exploited due to the implication of unusually expressed micro-RNA in numerous disorders such as cancer, cardiovascular diseases and HIV infections.

Browse the full report with request TOC at http://www.transparencymarketresearch.com/chiropractic-care-market.html.

The global micro-RNA market if categorized into:

Applications Research Diagnosis Therapeutics Technology Purification Labeling Linear amplification Microarrays qRT-PCR Inhibition

Globally, North America and Europe are the leading regions with booming micro-RNA market. Emerging economies of Asia such as India, Japan, China and Singapore as well as the Middle East and Latin American countries are also expected to show soaring progress in the growth of micro-RNA market.

One of the key factors driving the global micro-RNA market is provision of large scale funding by public and private sectors. Other factors responsible for the growth of this market are growing interest of pharmaceutical and biotechnological companies in conducting research on micro-RNAs and identification of micro-RNA role in different disease classes.

Some of the major players contributing to the global micro-RNA market comprises Access Pharmaceuticals, Agilent Technologies, Astrazeneca Pharmaceuticals LP, Benitec Biopharma Limited, Calando Pharmaceuticals, Inc., Covance, Inc., Eli Lilly and Co., F. Hoffman-La Roche AG, Illumina, Inc., Novartis International AG, Senesco Technologies, Inc., Sirnaomics, Inc., Tekmira Pharmaceuticals Corporation and Thermo Fisher Scientific, Inc.

Related Report : Depression Drug Market http://www.transparencymarketresearch.com/depression-drug-market.html

Go here to read the rest:
Research Report on Micro-RNA Market Analysis, Trends And Forecast, 2013 - 2019

Recommendation and review posted by Bethany Smith

Genetic Diseases

The age of genetics has arrived. Society is in the midst of a genetic revolution that some futurists predict will have a greater impact on the culture than the industrial revolution. So, in this essay we are going to look at the area of genetic engineering.

The future of genetics, like that of any other technology, offers great promise but also great peril. Nuclear technology has provided nuclear medicine, nuclear energy, and nuclear weapons. Genetic technology offers the promise of a diverse array of good, questionable, and bad technological applications. Christians, therefore, must help shape the ethical foundations of this technology and its future applications.

How powerful a technology is genetic engineering? For the first time in human history, it is possible to completely redesign existing organisms, including man, and to direct the genetic and reproductive constitution of every living thing. Scientists are no longer limited to breeding and cross-pollination. Powerful genetic tools allow us to change genetic structure at the microscopic level and bypass the normal processes of reproduction.

For the first time in human history, it is also possible to make multiple copies of any existing organism or of certain sections of its genetic structure. This ability to clone existing organisms or their genes gives scientists a powerful tool to reproduce helpful and useful genetic material within a population.

Scientists are also developing techniques to treat and cure genetic diseases through genetic surgery and genetic therapy. They can already identify genetic sequences that are defective, and soon scientists will be able to replace these defects with properly functioning genes.

At this point, let's take a look at the nature of genetic diseases. Genetic diseases arise from a number of causes. The first are single-gene defects. Some of these single-gene diseases are dominant and therefore cannot be masked by a second normal gene on the homologous chromosome (the other strand of a chromosome pair). An example is Huntington's chorea (a fatal disease that strikes in the middle of life and leads to progressive physical and mental deterioration). Many other single-gene diseases are recessive and are expressed only when both chromosomes have a defect. Examples of these diseases are sickle-cell anemia, which leads to the production of malformed red blood cells, and cystic fibrosis, which leads to a malfunction of the respiratory and digestive systems.

Another group of single-gene diseases includes the sex-linked diseases. Because the Y chromosome in men is much shorter than the X chromosome it pairs with, many genes on the X chromosome are absent on the homologous Y chromosome. Men, therefore, will show a higher incidence of genetic diseases such as hemophilia or color blindness. Even though these are recessive, males do not have a homologous gene on their Y chromosome that could contain a normal gene to mask it.

Another major cause of genetic disease is chromosomal abnormalities. Some diseases result from an additional chromosome. Down's syndrome is caused by trisomy-21 (three chromosomes at chromosome twenty-one). Klinefelter's syndrome results from the addition of an extra X chromosome (these men have a chromosome pattern that is XXY). Other genetic defects result from the duplication, deletion, or rearrangement (called translocation) of a gene sequence.

Genetic engineering offers the promise of eventually treating and curing these genetic defects. Although this is a promise in the future, we are already involved in genetic counseling and the significant ethical concerns it presents. Let's turn now to look at the topic of genetic counseling.

Here is the original post:
Genetic Engineering - LeaderU.com

Recommendation and review posted by Bethany Smith

Human Genetic Engineering - A Hot Issue! Human genetic engineering is a hot topic in the legislative and executive branches of the U.S. government. Time will tell how committed the United States will be regarding the absolute ban on human cloning.

Human Genetic Engineering - Position of the U.S. Government Human genetic engineering has made its way to Capitol Hill. On July 31, 2001, the House of Representatives passed a bill which would ban human cloning, not only for reproduction, but for medical research purposes as well. The Human Cloning Prohibition Act of 2001, sponsored by Rep. Weldon (R-fL) and co-sponsored by over 100 Representatives, passed by a bipartisan vote of 265-to-162. The Act makes it unlawful to: "1) perform or attempt to perform human cloning, 2) participate in an attempt to perform cloning, or 3) ship or receive the product of human cloning for any purpose." The Act also imposes penalties of up to 10 years imprisonment and no less than $1,000,000 for breaking the law. The same bill, sponsored by Sen. Brownback (R-kS), is currently being debated in the Senate.

The White House also opposes "any and all attempts to clone a human being; [they] oppose the use of human somatic cell nuclear transfer cloning techniques either to assist human reproduction or to develop cell or tissue-based therapies."

Human Genetic Engineering - The Problems There are many arguments against human genetic engineering, including the established safety issues, the loss of identity and individuality, and human diversity. With therapeutic cloning, not only do the above issues apply, but you add all the moral and religious issues related to the willful killing of human embryos. Maybe the greatest concern of all is that man would become simply another man-made thing. As with any other man-made thing, the designer "stands above [its design], not as an equal but as a superior, transcending it by his will and creative prowess." The cloned child will be dehumanized. (See, Leon Kass, Preventing a Brave New World: Why we should ban human cloning now, New Republic Online, May 21, 2001.)

Human Genetic Engineering - A Final Thought Human genetic engineering leads to man usurping God as the almighty creator and designer of life. No longer will a child be considered a blessing from God, but rather, a product manufactured by a scientist. Man will be a created being of man. However, man was always intended to be a created being of God, in His absolute love, wisdom and glory.

Learn More Now!

Like this information? Help us by sharing it with others. What is this?

See the rest here:
Human Genetic Engineering - AllAboutPopularIssues.org

Recommendation and review posted by Bethany Smith

The medical genetics of Jews is the study, screening and treatment of genetic disorders that are more common in particular Jewish populations than in the population as a whole.[1] The genetics of Ashkenazi Jews have been particularly well-studied, resulting in the discovery of many genetic disorders that are associated with this ethnic group. In contrast, the medical genetics of Sephardic Jews and Oriental Jews are more complicated, since they are more genetically diverse and there are consequently no genetic disorders that are more common in these groups as a whole; instead they tend to have the genetic diseases that are common in their various countries of origin.[1][2] Several organizations, such as Dor Yeshorim,[3] offer screening for Ashkenazi genetic diseases, and these screening programs have had a significant impact, in particular by reducing the number of cases of TaySachs disease.[4]

Different ethnic groups tend to suffer from different rates of hereditary diseases, with some being more common, and some less common. Hereditary diseases, particularly hemophilia were recognized early in Jewish history, even being described in the Talmud.[5] However, the scientific study of hereditary disease in Jewish populations was initially hindered by the shadow of the racially selective ideas of eugenics and "racial hygiene", which tried to describe various ethnic groups as inferior.[6][7]

However, modern studies on the genetics of particular ethnic groups have the tightly-defined purpose of avoiding the birth of children with genetic diseases, or identifying people at particular risk of developing a disease in the future.[6] Consequently, the Jewish community has been very supportive of modern genetic testing programs, although this unusually high degree of cooperation has raised concerns that it might lead to the false perception that Jews are more susceptible to genetic diseases than other groups of people.[5]

However, most populations contain hundreds of alleles that could potentially cause disease and most people are heterozygotes for one or two recessive alleles that would be lethal in a homozygote.[8] Although the overall frequency of disease-causing alleles does not vary much between populations, the practice of consanguineous marriage (marriage between second cousins or closer relatives) is common in some Jewish communities, which produces a small increase in the number of children with congenital defects.[9]

According to Daphna Birenbaum Carmeli at the University of Haifa, Jewish populations have been studied more thoroughly than most other human populations because:[10]

The result is a form of ascertainment bias. This has sometimes created an impression that Jews are more susceptible to genetic disease than other populations. Carmeli writes, "Jews are over-represented in human genetic literature, particularly in mutation-related contexts."[10] Another factor that may aid genetic research in this community is that Jewish culture results in excellent medical care, which is coupled to a strong interest in the community's history and demography.[11]

This set of advantages have led to Ashkenazi Jews in particular being used in many genetic studies, not just in the study of genetic diseases. For example, a series of publications on Ashkenazi centenarians established that their longevity was strongly inherited and associated with lower rates of age-related diseases.[12] This "healthy aging" phenotype may be due to higher levels of telomerase in these individuals.[13]

Although there is no reason to think that the Ashkenazi Jewish population has any more or fewer mutations than other ethnic groups, evidence for a significant population bottleneck suggests that deleterious alleles may have become more prevalent in the population due to genetic drift.[14] As a result, this group has been particularly intensively-studied, so many mutations have been identified as common in Ashkenazis.[15] Of these diseases, many also occur in other Jewish groups and in non-Jewish populations, although the specific mutation which causes the disease may vary between populations. For example, two different mutations in the glucocerebrosidase gene causes Gaucher's disease in Ashkenazis, which is their most common genetic disease, but only one of these mutations is found in non-Jewish groups.[4] A few diseases are unique to this group: for example familial dysautonomia is almost unknown in other populations.[4]

TaySachs disease, a fatal illness of children that causes mental deterioration prior to death, was historically more prevalent among Ashkenazi Jews,[17] although high levels of the disease are also found in some Pennsylvania Dutch, Southern Louisiana Cajun and Eastern Quebec French Canadian populations.[18] Since the 1970s, however, proactive genetic testing has been quite effective in eliminating TaySachs from the Ashkenazi Jewish population.[19]

Gaucher's disease, in which lipids accumulate in inappropriate locations, occurs most frequently among Ashkenazi Jews;[20] the disease is carried by roughly 1 in every 15 Ashkenazi Jews, compared to 1 in 100 of the general American population.[21] Gaucher's disease can cause brain damage and seizures, but these effects are not usually present in the form manifested among Ashkenazi Jews; while sufferers still bruise easily, and it can still potentially rupture the spleen, it generally has only a minor impact on life expectancy.

Follow this link:
Medical genetics of Jews - Wikipedia, the free encyclopedia

Recommendation and review posted by Bethany Smith

Genetic disorder Classification and external resources MeSH D030342

A genetic disorder is an illness caused by one or more abnormalities in the genome, especially a condition that is present from birth (congenital). Most genetic disorders are quite rare and affect one person in every several thousands or millions.

Genetic disorders may or may not be heritable, i.e., passed down from the parents' genes. In non-heritable genetic disorders, defects may be caused by new mutations or changes to the DNA. In such cases, the defect will only be heritable if it occurs in the germ line. The same disease, such as some forms of cancer, may be caused by an inherited genetic condition in some people, by new mutations in other people, and mainly by environmental causes in still other people. Whether, when and to what extent a person with the genetic defect or abnormality will actually suffer from the disease is almost always affected by environmental factors and events in the person's development.

Some types of recessive gene disorders confer an advantage in certain environments when only one copy of the gene is present.[1]

A single gene disorder is the result of a single mutated gene. Over 4000 human diseases are caused by single gene defects. Single gene disorders can be passed on to subsequent generations in several ways. Genomic imprinting and uniparental disomy, however, may affect inheritance patterns. The divisions between recessive and dominant types are not "hard and fast", although the divisions between autosomal and X-linked types are (since the latter types are distinguished purely based on the chromosomal location of the gene). For example, achondroplasia is typically considered a dominant disorder, but children with two genes for achondroplasia have a severe skeletal disorder of which achondroplasics could be viewed as carriers. Sickle-cell anemia is also considered a recessive condition, but heterozygous carriers have increased resistance to malaria in early childhood, which could be described as a related dominant condition.[4] When a couple where one partner or both are sufferers or carriers of a single gene disorder and wish to have a child, they can do so through in vitro fertilization, which means they can then have a preimplantation genetic diagnosis to check whether the embryo has the genetic disorder.[5]

Only one mutated copy of the gene will be necessary for a person to be affected by an autosomal dominant disorder. Each affected person usually has one affected parent.[6] The chance a child will inherit the mutated gene is 50%. Autosomal dominant conditions sometimes have reduced penetrance, which means although only one mutated copy is needed, not all individuals who inherit that mutation go on to develop the disease. Examples of this type of disorder are Huntington's disease,[7]neurofibromatosis type 1, neurofibromatosis type 2, Marfan syndrome, hereditary nonpolyposis colorectal cancer, and hereditary multiple exostoses,Tuberous sclerosis, Von Willebrand disease, acute intermittent porphyria which is a highly penetrant autosomal dominant disorder. Birth defects are also called congenital anomalies.

Two copies of the gene must be mutated for a person to be affected by an autosomal recessive disorder. An affected person usually has unaffected parents who each carry a single copy of the mutated gene (and are referred to as carriers). Two unaffected people whom each carry one copy of the mutated gene have a 25% chance with each pregnancy of having a child affected by the disorder. Examples of this type of disorder are Medium-chain acyl-CoA dehydrogenase deficiency, cystic fibrosis, sickle-cell disease, Tay-Sachs disease, Niemann-Pick disease, spinal muscular atrophy, and Roberts syndrome. Certain other phenotypes, such as wet versus dry earwax, are also determined in an autosomal recessive fashion.[8][9]

X-linked dominant disorders are caused by mutations in genes on the X chromosome. Only a few disorders have this inheritance pattern, with a prime example being X-linked hypophosphatemic rickets. Males and females are both affected in these disorders, with males typically being more severely affected than females. Some X-linked dominant conditions, such as Rett syndrome, incontinentia pigmenti type 2 and Aicardi syndrome, are usually fatal in males either in utero or shortly after birth, and are therefore predominantly seen in females. Exceptions to this finding are extremely rare cases in which boys with Klinefelter syndrome (47,XXY) also inherit an X-linked dominant condition and exhibit symptoms more similar to those of a female in terms of disease severity. The chance of passing on an X-linked dominant disorder differs between men and women. The sons of a man with an X-linked dominant disorder will all be unaffected (since they receive their father's Y chromosome), and his daughters will all inherit the condition. A woman with an X-linked dominant disorder has a 50% chance of having an affected fetus with each pregnancy, although it should be noted that in cases such as incontinentia pigmenti, only female offspring are generally viable. In addition, although these conditions do not alter fertility per se, individuals with Rett syndrome or Aicardi syndrome rarely reproduce.[citation needed]

X-linked recessive conditions are also caused by mutations in genes on the X chromosome. Males are more frequently affected than females, and the chance of passing on the disorder differs between men and women. The sons of a man with an X-linked recessive disorder will not be affected, and his daughters will carry one copy of the mutated gene. A woman who is a carrier of an X-linked recessive disorder (XRXr) has a 50% chance of having sons who are affected and a 50% chance of having daughters who carry one copy of the mutated gene and are therefore carriers. X-linked recessive conditions include the serious diseases hemophilia A, Duchenne muscular dystrophy, and Lesch-Nyhan syndrome, as well as common and less serious conditions such as male pattern baldness and red-green color blindness. X-linked recessive conditions can sometimes manifest in females due to skewed X-inactivation or monosomy X (Turner syndrome).

Y-linked disorders, also called holandric disorders, are caused by mutations on the Y chromosome. These conditions display may only be transmitted from the heterogametic sex (e.g. male humans) to offspring of the same sex. More simply, this means that Y-linked disorders in humans can only be passed from men to their sons; females can never be affected because they do not possess Y allosomes.

Read more here:
Genetic disorder - Wikipedia, the free encyclopedia

Recommendation and review posted by Bethany Smith

Welcome to Greater Washington Maternal-Fetal Medicine and Genetics, serving the Mid-Atlantic region in the field of Maternal-Fetal and Genetics specialty. Our physicians, Thomas Pinckert, M.D., Pamela Lewis Matia, M.D., Michael Gallagher, M.D., Gena T. Manley, M.D., and Dr. Dana Figueroa Marzilli, M.D. have expertise in all aspects of Maternal-Fetal Medicine and high risk pregnancy.

Finding out that you are having a baby can be the most joyous occasion in a women's life. However, it may also be a time of concern, especially if you are diagnosed with a high risk pregnancy or if you are worried about the health of your baby. Greater Washington Maternal-Fetal Medicine and Genetics has experienced physicians and staff who have expertise in complicated maternal fetal medical conditions, multiple gestations, fetal diagnosis and genetic disorders such as Tay-Sachs disease. By using state-of-the-art ultrasound and diagnostic tests, our team evaluates your health and the health of your baby before delivery. We then work closely with you, your family and your health care professionals to develop a care plan to manage any problems identified. Throughout your pregnancy, we will ensure that you understand your medical conditions and the options available to you. All of your questions or concerns will be addressed thoroughly and sensitively.

Original post:
Welcome to Greater Washington Maternal-Fetal Medicine and ...

Recommendation and review posted by Bethany Smith

Skunk House Genetics
Transplanted into larger containers 4/16/2014.

By: New England Grower

Read more from the original source:
Skunk House Genetics - Video

Recommendation and review posted by Bethany Smith

Human Genetics and Personalized Medicine, Dr. David Cox
Human Genetics, Personalized Medicine and Improved Health Outcomes: Hype or Reality? Dr. David Cox, Senior Vice President and Chief Scientific Officer Biothe...

By: Linus Pauling Memorial Lecture Series

Go here to read the rest:
Human Genetics and Personalized Medicine, Dr. David Cox - Video

Recommendation and review posted by Bethany Smith

Attack Of The B Team Advanced Genetics Tutorial
this is how you can be a mutated freak

By: timothykok333

Read this article:
Attack Of The B Team Advanced Genetics Tutorial - Video

Recommendation and review posted by Bethany Smith

Many human diseases are caused by defective genes.

All of these diseases are caused by a defect at a single gene locus. (The inheritance is recessive so both the maternal and paternal copies of the gene must be defective.) Is there any hope of introducing functioning genes into these patients to correct their disorder? Probably.

Other diseases also have a genetic basis, but it appears that several genes must act in concert to produce the disease phenotype. The prospects of gene therapy in these cases seems far more remote.

It is a disease of young children because, until recently, the absence of an immune system left them prey to infections that ultimately killed them.

Once the virus has infected the target cells, this RNA is reverse transcribed into DNA and inserted into the chromosomal DNA of the host.

The first attempts at gene therapy for SCID children (in 1990), used their own T cells (produced following ADA-PEG therapy) as the target cells.

In June of 2002, a team of Italian and Israeli doctors reported on two young SCID patients that were treated with their own blood stem cells that had been transformed in vitro with a retroviral vector carrying the ADA gene. After a year, both children had fully-functioning immune systems (T, B, and NK cells) and were able to live normal lives without any need for treatment with ADA-PEG or immune globulin (IG). The doctors attribute their success to first destroying some of the bone marrow cells of their patients to "make room" for the transformed cells.

Nine years later (August 2011) these two patients are still thriving and have been joined by 28 other successfully-treated children most of whom no longer need to take ADA-PEG.

Gene therapy has also succeeded for 20 baby boys who suffered from another form of severe combined immunodeficiency called X-linked SCID because it is caused by a mutated X-linked gene encoding a subunit called c (gamma-c) of the receptor for several interleukins, including interleukin-7 (IL-7).

IL-7 is essential for converting blood stem cells into the progenitors of T cells. [View]. Boys with X-linked SCID can make normal B cells, but because B cells need T-helper cells to function, these boys could make neither cell-mediated nor antibody-mediated immune responses and had to live in a sterile bubble before their treatment.

View original post here:
Gene Therapy I - RCN Corporation

Recommendation and review posted by Bethany Smith

Gene therapy is a new science as of now and still in its infancy stage. In this procedure, genes from one individuals cells are injected into another, mostly for the cure of certain diseases. Read on to know all about this (X-Men type) science.

Gene Therapy: History and Future

A method or therapy through which nucleic acids are transferred to the somatic cells in order to treat a particular disease is termed as gene therapy. Over expressing the proteins or repairing the defective genes are two possible...

Types of Gene Therapy

The two gene therapy types are germ line gene therapy and somatic gene therapy. While the germ line type is aimed at permanent manipulation of genes in the germ cells, the somatic gene therapy refers to correction of genes in the...

Gene Therapy Pros and Cons

Some swear by its therapeutic potential, whereas some view gene therapy as violating God's powers. Gene therapy pros and cons has scientists, religious figures and even common man divided on its rationality. Let us understand what...

Gene Therapy for Human Severe Combined Immunodeficiency Disease

Severe combined immunodeficiency (SCID) is a life-threatening disease, also known as the 'Boy in the Bubble' syndrome. Here's more.

Gene Therapy for Cancer

View original post here:
Gene Therapy | Buzzle.com

Recommendation and review posted by Bethany Smith

Spinal Cord Injury Back Problems And Corsets
I got this Hoke Corset to try and regain some of the lateral, frontal and strength that I lost during this 4 years of being bed-bound with my old wound and l...

By: Ralph Raymond

Go here to see the original:
Spinal Cord Injury Back Problems And Corsets - Video

Recommendation and review posted by sam

Spinal cord injury (SCI) Rehabilitation revolutionary Machine
Credited to: Dr.Zahra K. Moussavi Mohammad Reza Morovati Samaneh Baghbani University of Manitoba.

By: Ahmad Byagowi

Read more here:
Spinal cord injury (SCI) Rehabilitation revolutionary Machine - Video

Recommendation and review posted by sam

Arachnoiditis (spinal cord injury) Survivor: Portrait Project In Progress
FREE Pet Portraits to those who donate $65 or more to this project by April 29, 2014.This is the latest update to Arachnoiditis Survivor: A Portrait of Resil...

By: Sheila Kalkbrenner

Read the rest here:
Arachnoiditis (spinal cord injury) Survivor: Portrait Project In Progress - Video

Recommendation and review posted by sam

When Mike Towns went in for cardiac surgery recently, doctors hoped to save two things: his heart, and a few units of blood.

The 69-year-old retired owner of a general store in Duoro, a small town outside Peterborough, Ont., was having his aortic valve replaced at Torontos Peter Munk Cardiac Centre, where doctors have piloted an innovative bedside-testing regime to reduce the amount of blood and blood products pumped into patients at the end of heart surgery.

The new protocol has driven down the cardiac centres use of red blood cells by 20 per cent and blood products by 40 per cent, saving the hospital more than $1-million so far.

The pilot project, which is set to expand to a dozen other Canadian hospitals beginning in September, is part of a larger movement toward conserving blood in this country.

Experts say that movement will be critical to prevent blood shortages as the population ages. The older the baby boomers get, the more they are expected to require complex treatments that include transfusions and the less they are expected to roll up their sleeves and donate blood.

Its a looming demographic development that could begin to drain the countrys blood banks and drive up the cost of a system that already costs more than $465-million a year in provincial and territorial funding to operate.

There are calculations that suggest now that our blood has run out we only produce just enough to support cancer patients and surgical patients right now. Just enough, said Stuart McCluskey, medical director of the blood-conservation program at Peter Munk Cardiac Centre, which is located at Toronto General Hospital.

Theres a finite amount of donors. This is such an important initiative because the only way to make the balance sheet work is to reduce the utilization of blood when its not needed.

A 2012 study in the journal Transfusion projected that demand for blood could begin exceeding supply the same year the paper was published.

The researchers dug into the 2008 figures for blood donation and blood use in Ontario a province they considered a fair proxy for supply and demand rates in the rest of the country and then extrapolated out to the year 2036. If the trends hold, red blood cell demand is forecasted to outstrip supply as soon as 2012, the study concluded.

Read the original here:
How doctors are using a simple test in surgery to save blood and money

Recommendation and review posted by Bethany Smith

Phoenix, Arizona (PRWEB) April 21, 2014

The Center for Joint Regeneration is now offering several stem cell procedures for patients with knee arthritis to help avoid the need for joint replacement. The procedures are offered by Board-certified and Fellowship-trained orthopedic doctors, with the stem cells being derived from either bone marrow or amniotic fluid. For more information and scheduling with the top stem cell providers in the greater Phoenix area, call (480) 466-0980.

For the hundreds of thousands of individuals who undergo a knee replacement every year, it should be considered an absolute last resort, after other conservative options have failed. Although the vast majority of knee replacements do well, the implants are not meant to last forever, the surgery does have potential risks and the biomechanics of the knee are significantly changed with the prosthetic implants.

Stem cells for knee arthritis have the potential to repair and regenerate damage from arthritis and relieve pain substantially. Center for Joint Regeneration offers these outpatient procedures with several methods.

The first involves usage of the patient's own bone marrow, with a short harvesting procedure, processing the bone marrow, and injection at the same setting into one or both knees.

Another method is with amniotic derived stem cell rich material, which not only possesses concentrated stem cells but also a significant amount of growth factors and hyaluronic acid. The material is a meteorologically privileged and has been used tens of thousands of times around the world with minimal adverse events.

Platelet rich plasma therapy for knee degeneration is also offered. PRP therapy has been shown in recent studies at Hospital for Special Surgery to work well for pain relief from knee arthritis. It also offers the ability to preserve knee cartilage based on serial MRI's performed in the study.

So far, clinical outcomes with the stem cell regenerative procedures have been excellent. The Board-Certified orthopedic doctors at Center for Joint Regeneration, Doctors Farber and Dewanjee, are exceptionally well trained and highly skilled at these outpatient procedures.

For those individuals looking to avoid or delay the need for knee replacement due to degenerative arthritis, call the Center for Joint Regeneration today at (480) 466-0980. The Center offers stem cell treatments Phoenix and Scottsdale trust!

Go here to see the original:
Center for Joint Regeneration Now Offering Several Stem Cell Procedures for Patients to Avoid Knee Replacement

Recommendation and review posted by Bethany Smith

Sarah and Marc discovered that in the Philadelphia area, even if parents realized umbilical cords were more than just waste products of childbirth, there was no easy way to donate the tissue. So they established the Mason Shaffer Foundation to change that.

This month, Temple University Hospital launched a program in collaboration with the foundation and the New Jersey Cord Blood Bank to educate expectant parents and enable them to donate in a convenient way - at no charge to them or Temple. The foundation provides the educational material, and the cord-blood bank covers the collection costs, which are offset by health insurance reimbursement for transplants.

Three years ago, Lankenau Medical Center in Wynnewood became the foundation's first cord-blood donation center.

Temple, however, is expected to help fill the desperate need for a more racially diverse cord-blood stockpile. That need was recognized by the federal Stem Cell Therapeutic and Research Act of 2005, which included funding that will help underwrite the first year of Temple's program.

Of the 3,200 babies delivered at Temple each year, 65 percent are African American, and 30 percent are Hispanic.

"Ethnically diverse groups are underrepresented as cord-blood donors and have a lower chance of finding a matched donor," said Dimitrios Mastrogiannis, Temple's director of maternal fetal medicine.

"Our biggest challenge is building diversity," echoed Roger Mrowiec, scientific director of Community Blood Services in Montvale, N.J., which runs the New Jersey Cord Blood Bank. "A Caucasian has about a 95 percent chance of finding a match. For Hispanics, that falls to 70 percent, and for African Americans, it's only 60 percent."

Mrowiec spoke at a Temple news conference where the grown-ups were happily upstaged by the foundation's eponymous poster boy. Although Mason is small for his age and blind in his left eye, his transplant cured his disease: malignant infantile osteopetrosis.

"Do you know why we're here?" his mother asked him.

"Because I got cells that fixed my bones," the precocious preschooler piped up.

Follow this link:
Umbilical cord blood transplants become standard

Recommendation and review posted by Bethany Smith

Royale L #39;Opulent Rejuv Facial Essence
1950.00 FOR ORDERS: +639277823446, +639274865256 http://www.facebook.com/RoyaleHealthWellnessBeauty Well, there is art and science to battle against skin ...

By: Maricel Tan

Read more:
Royale L'Opulent Rejuv Facial Essence - Video

Recommendation and review posted by Bethany Smith

Ankle arthritis; 4 months after stem cell therapy by Dr Harry Adelson
Craig discusses his results from his stem cell therapy by Dr Harry Adelson for his arthritic ankle http://www.docereclinics.com.

By: Harry Adelson, N.D.

Continue reading here:
Ankle arthritis; 4 months after stem cell therapy by Dr Harry Adelson - Video

Recommendation and review posted by Bethany Smith

Madison #39;s Before After Stem Cell Therapy
Had step cell therapy procedure on 4/14/14 and we were seeing noticeable results only 4 short days later.

By: Jaie Locke

Read this article:
Madison's Before & After Stem Cell Therapy - Video

Recommendation and review posted by Bethany Smith

stem cell therapy treatment for Global Developmental Delay with Severe Mental Retardation
improvement seen in just 3 months after stem cell therapy treatment for Global Developmental Delay with Severe Mental Retardation by dr alok sharma, mumbai, ...

By: Neurogen Brain and Spine Institute

Continue reading here:
stem cell therapy treatment for Global Developmental Delay with Severe Mental Retardation - Video

Recommendation and review posted by Bethany Smith

stem cell therapy treatment for cerebral palsy with mental retardation with low vision by dr alok
improvement seen in just 3 months after stem cell therapy treatment for cerebral palsy with mental retardation with low vision by dr alok sharma, mumbai, ind...

By: Neurogen Brain and Spine Institute

Excerpt from:
stem cell therapy treatment for cerebral palsy with mental retardation with low vision by dr alok - Video

Recommendation and review posted by Bethany Smith

Love your regular ham sandwich or grilled sausages? Experts say those who consume too much processed meat risk a higher chance of colorectal cancer if they possess a common gene variant identified as GATA3.

According to Dr. Jane Figueiredo, of the Keck School of Medicine at the University of Southern California, the new study published in PLOS Genetics is the first to understand whether some individuals are at higher or lower risk based on their genomic profile.

"This information can help us better understand the biology and maybe in the future lead to targeted prevention strategies" said Dr Figueiredo.

Pointing out that"diet is a modifiable risk factor for colorectal cancer",Dr Figueiredo andthe research team expanded on earlier studies ondiet, especially one that's high in red or processed meat and colorectal cancer risk.

The team looked at more than 9,000 colorectal cancer cases and a similar number of controls and the interaction between red meat, processed meat, fiber, fruit and vegetables, and colorectal cancer risk.

They founda significant interaction between the genetic variant "rs4143094"linked to a gene called GATA3and processed meat.

"The possibility that genetic variants may modify an individual's risk for disease based on diet has not been thoroughly investigated but represents an important new insight into disease development," concludes Dr. Li Hsu, the lead statistician on the study.

Read the original:
Gene link found in colorectal cancer risk from processed meats

Recommendation and review posted by Bethany Smith

Rep. Carolyn Partridge

The Senate passed H.112, a bill requiring the labeling of food produced with genetic engineering, on a strong 28-2 vote. There were relatively few substantive changes made to the bill, which originated in the House.

One big change was the addition of the "Genetically Engineered Food Labeling Special Fund." The purpose of the fund would be to help pay for implementation costs including rulemaking. It could also be used to pay for liabilities if the state is sued. The fund could accept public and private donations, gifts, grants, and bequests, as well as money appropriated by the General Assembly. The concept of a special fund is not a new one -- there are several special funds already in existence.

Another change made by the Senate is the effective date. The House version, passed in 2013, had two possibilities for the effective date depending on which came first. One was a trigger of 18 months after two other states enacted legislation with requirements substantially comparable for the labeling of food produced from genetic engineering, the other was a "drop dead" date of July 1, 2015. Our intention was to give our producers time to use up existing packaging and/or reformulate their products so as to use non-GE ingredients if they wished. The Senate did not include a trigger but decided on July 1, 2016. This, too, would allow a two-year period for producers to adjust.

One concern has been that if we didn't include a trigger, we would be sued. However, in 2012, when our committee worked on this bill the first time, we took testimony from an attorney for the biotechnology industry indicating that regardless of a trigger, they would consider this an imminent threat and initiate a lawsuit under the legal tenet of "ripeness." Interestingly, both Maine and Connecticut have passed similar bills that included triggers and to my knowledge they have not been sued.

The House Agriculture and Forest Products Committee (HAFPC) is reviewing H.112 and will have several options. We can concur with the Senate proposal, we can concur with further proposals of amendment, or if we really disagree with what has been done, we can ask for a Committee of Conference. The House Judiciary Committee will be reviewing its sections of the bill and because the Senate included the addition of a fund, the Appropriations Committee will take a look at it as well. I expect that we will be making our decision next week. If we choose to concur, the bill will go to Governor Peter Shumlin.

The HAFPC has also been working on S.70, a bill relating to the delivery of raw (unpasteurized) milk at farmers' markets. When we passed the original raw milk bill several years ago, we created a two-tiered system. Producers at the Tier 1 level can sell up to 12.5 gallons of milk per day. Tier 2 can sell up to 40 gallons per day but have more stringent testing and labeling requirements.

For both Tier 1 and Tier 2, we allow customers to purchase milk at the farm. Tier 2 producers can also deliver milk to people's homes once the customer has visited the farm and pre-paid for their milk. Because raw milk is not pasteurized, it is important that it be handled properly and kept at 40 degrees Fahrenheit or less so delivery must be done in refrigerated units or cooler-contained ice baths.

The majority of our committee is on board regarding the delivery of raw milk to farmers' markets and is considering other changes to the law as well. Food safety is our number one concern but we would also like producers to be able to expand their markets where possible. One consideration is to allow for weekly aggregate sales rather than a hard daily limit of 40 gallons.

The Education Governance bill, H.883, continues to make its way through the process. The Ways and Means Committee did a strike-all amendment to the Education Committee's version of the bill, which was a bit unusual. Now the Appropriations Committee is working on it and may do a strike-all to the Ways and Means version.

View original post here:
GMO update

Recommendation and review posted by Bethany Smith

Research assistant Natalie Thomas pulls a slice of a cancerous tumor for analysis at the Anschutz Medical Campus. (Andy Cross, The Denver Post)

Ellen Smith received a death sentence for her advanced lung cancer five years ago, but it was commuted by a revolution in human genetics, drug therapies and clinical approaches unfolding at the University of Colorado Hospital.

The advances have saved her life, by her reckoning, four times.

The accelerating speed of DNA sequencing, drug development and data analysis has led UCHealth, the University of Colorado Medical School and Children's Hospital Colorado to join in an effort to fundamentally change the way they care for patients.

The partnership will invest more than $63 million over the next five years to create a new division, adding clinicians, genetic counselors, researchers and advanced practice nurses and also expanding a DNA bank and advanced data warehouse. It's called the Center for Personalized Medicine and Biomedical Informatics.

The pioneering field of personalized medicine uses molecular analysis to determine a patient's predisposition to developing certain diseases and to deliver tailored medical treatment.

"There is no doubt in my mind that this will change how we treat disease, how we teach our students, how physicians work, how we raise our kids and how we conduct public health policy," Dr. David Schwartz, chair of the CU Department of Medicine, said of the center.

The DNA bank, Schwartz said, probably will require a year of discussion with physicians, academicians, lawyers, ethicists and patient advocates about what it really means to secure patients' genetic blueprints and how they should be used.

While the center will be based on the Anschutz Medical Campus in Aurora, it will serve UCHealth's five hospitals and Children's Hospital. The DNA bank would sequence and analyze samples from around the region.

The benefits of personalized medicine have been evident for several years in cancer treatment, said Dr. Dan Theodorescu, director of the CU Cancer Center. It's why the center's survival rates are significantly better for certain types of cancers than the average national outcomes, he said. The new center will bring these kinds of lifesaving therapies to all disease fronts while providing more laboratory and analytical power to evaluate cancer DNA, he said.

Link:
CU system resets health care with $63M personalized medicine division

Recommendation and review posted by Bethany Smith